Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial

The Lancet

Volumn 376, Issue 9752, 2010, Pages 1543-1551

  De Zeeuw, Dick ^a   Agarwal, Rajiv ^b   Amdahl, Michael ^c   Audhya, Paul ^c   Coyne, Daniel ^d   Garimella, Tushar ^c   Parving, Hans Henrik ^e   Pritchett, Yili ^c   Remuzzi, Giuseppe ^f   Ritz, Eberhard ^g   Andress, Dennis ^c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ABBOTT LABORATORIES   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e AARHUS UNIVERSITY   (Denmark)

^f MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^g UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; INSULIN; INSULIN DERIVATIVE; PARATHYROID HORMONE; PARICALCITOL; PLACEBO; VITAMIN D RECEPTOR;

ADD ON THERAPY; ADULT; AGED; ALBUMIN URINE LEVEL; ALBUMINURIA; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; ERECTILE DYSFUNCTION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCALCEMIA; HYPERTENSION; HYPOPARATHYROIDISM; LABORATORY TEST; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MICROALBUMINURIA; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PARATHYROID HORMONE BLOOD LEVEL; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; STOMACH PARESIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 78149359262     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)61032-X     Document Type: Article

References (34)

1. D de Zeeuw, HJ Lambers Heerspink, RT Gansevoort, SJL Bakker How to improve renal outcome in diabetes and hypertension - the importance of early screening for and treatment of microalbuminuria Eur Nephrol 3 2009 13 15
2. P Ruggenenti, A Perna, G Remuzzi on behalf of the investigators of the Gisen Group Retarding progression of chronic renal disease: the neglected issue of residual proteinuria Kidney Int 63 2003 2254 2261
3. WB Eijkelkamp, Z Zhang, G Remuzzi Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial J Am Soc Nephrol 18 2007 1540 1546
4. JFE Mann, RE Schmieder, M McQueen on behalf of the ONTARGET investigators Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Lancet 372 2008 547 553
5. S Yusuf, KK Teo, J Pogue Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 2008 1547 1559
6. JF Mann, D Green, K Jamerson Avosentan for overt diabetic nephropathy J Am Soc Nephrol 21 2010 527 535
7. HL Heerspink, T Greene, JB Lewis Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria Nephrol Dial Transplant 23 2008 1946 1954
8. A Levin, GL Bakris, M Molitch Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease Kidney Int 71 2007 31 38
9. M Mizobuchi, J Morrissey, JL Finch Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats J Am Soc Nephrol 18 2007 1796 1806
10. X Tan, Y Li, Y Liu Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy J Am Soc Nephrol 17 2006 3382 3393
11. X Tan, X Wen, Y Liu Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-κB signaling J Am Soc Nephrol 19 2008 1741 1752
12. Z Zhang, L Sun, Y Wang Renoprotective role of the vitamin D receptor in diabetic nephropathy Kidney Int 73 2008 163 171
13. Z Zhang, Y Zhang, G Ning, DK Deb, J Kong, YC Li Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase Proc Natl Acad Sci USA 105 2008 15896 15901
14. R Agarwal, M Acharya, J Tian Antiproteinuric effect of oral paricalcitol in chronic kidney disease Kidney Int 68 2005 2823 2828
15. HJ Lambers Heerspink, R Agarwal, DW Coyne The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics Am J Nephrol 30 2009 280 286
16. US Department of Health and Human Services National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf May 2003 (accessed Sept 16, 2010).
17. P Alborzi, NA Patel, C Peterson Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial Hypertension 52 2008 249 255
18. S Fishbane, H Chittineni, M Packman, P Dutka, N Ali, N Durie Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial Am J Kidney Dis 54 2009 647 652
19. CC Szeto, KM Chow, BC Kwan, KY Chung, CB Leung, PK Li Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial Am J Kidney Dis 51 2008 724 731
20. M Freundlich, Y Quiroz, Z Zhang Suppression of renin-angiotensin gene expression in the kidney by paricalcitol Kidney Int 74 2008 1394 1402
21. YC Li, J Kong, M Wei, ZF Chen, SQ Liu, LP Cao 1,25-dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system J Clin Invest 110 2002 229 238
22. U Schwarz, K Amann, SR Orth, A Simonaviciene, S Wessels, E Ritz Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats Kidney Int 53 1998 1696 1705
23. HH Parving, F Persson, JB Lewis, EJ Lewis, NK Hollenberg for the AVOID Study Investigators Aliskiren combined with losartan in type 2 diabetes and nephropathy N Engl J Med 358 2008 2433 2446
24. M Bertoli, G Luisetto, A Ruffatti, M Urso, G Romagnoli Renal function during calcitriol therapy in chronic renal failure Clin Nephrol 33 1990 98 102
25. A Perez, R Raab, TC Chen, A Turner, MF Holick Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis Br J Dermatol 134 1996 1070 1078 (Pubitemid 26183140)
26. SG Rostand Ultraviolet light may contribute to geographic and racial blood pressure differences Hypertension 30 1997 150 156
27. JF Feneis, RR Arora Role of vitamin D in blood pressure homeostasis Am J Ther 2010 10.1097/MJT.0b013e3181d16999 published online Mar 5.
28. M Pfeifer, B Begerow, HW Minne, D Nachtigall, C Hansen Effects of a short-term vitamin D3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women J Clin Endocrinol Metab 86 2001 1633 1637
29. YC Li, G Qiao, M Uskokovic, W Xiang, W Zheng, J Kong Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure J Steroid Biochem Mol Biol 89-90 2004 387 392
30. L Vogt, F Waanders, F Boomsma, D de Zeeuw, G Navis Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan J Am Soc Nephrol 19 2008 999 1007
31. D Coyne, M Acharya, P Qiu Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD Am J Kidney Dis 47 2006 263 276 (Pubitemid 43121329)
32. K Kalantar-Zadeh, N Kuwae, DL Regidor Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients Kidney Int 70 2006 771 780
33. CS Shinaberger, JD Kopple, CP Kovesdy Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients Clin J Am Soc Nephrol 3 2008 1769 1776
34. M Teng, M Wolf, E Lowrie, N Ofsthun, JM Lazarus, R Thadhani Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy N Engl J Med 349 2003 446 456 (Pubitemid 36910023)